Zobrazeno 1 - 10 of 2 317 pro vyhledávání: '"Korpal M"'
1
Akademický článek
Detection of circulating tumor cells by means of machine learning using Smart-Seq2 sequencing.
Autor: Pastuszak K; Faculty of Electronics, Telecommunication and Informatics, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233, Gdańsk, Poland. krzpastu@pg.edu.pl.; Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210, Gdańsk, Poland. krzpastu@pg.edu.pl.; Centre of Biostatistics and Bioinformatics, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210, Gdańsk, Poland. krzpastu@pg.edu.pl., Sieczczyński M; Centre of Biostatistics and Bioinformatics, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210, Gdańsk, Poland., Dzięgielewska M; Faculty of Electronics, Telecommunication and Informatics, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233, Gdańsk, Poland., Wolniak R; Faculty of Electronics, Telecommunication and Informatics, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233, Gdańsk, Poland., Drewnowska A; Faculty of Electronics, Telecommunication and Informatics, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233, Gdańsk, Poland., Korpal M; Faculty of Electronics, Telecommunication and Informatics, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233, Gdańsk, Poland., Zembrzuska L; Faculty of Electronics, Telecommunication and Informatics, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233, Gdańsk, Poland., Supernat A; Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210, Gdańsk, Poland.; Centre of Biostatistics and Bioinformatics, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210, Gdańsk, Poland., Żaczek AJ; Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210, Gdańsk, Poland. azaczek@gumed.edu.pl.
Publikováno v: Scientific reports [Sci Rep] 2024 May 14; Vol. 14 (1), pp. 11057. Date of Electronic Publication: 2024 May 14.
Zobrazit plný text záznamu
2
Akademický článek
Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion.
Autor: Wang H; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina.; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Zhou Y; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology, Chengdu, Sichuan, P.R. China., Chu C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts., Xiao J; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology, Chengdu, Sichuan, P.R. China., Zheng S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts., Korpal M; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Korn JM; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Penaloza T; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina., Drake RR; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina.; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Gan W; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina., Gao X; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina.; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2023 Dec 01; Vol. 21 (12), pp. 1317-1328.
Zobrazit plný text záznamu
3
Akademický článek
Identification of 2-Sulfonyl/Sulfonamide Pyrimidines as Covalent Inhibitors of WRN Using a Multiplexed High-Throughput Screening Assay.
Autor: Parker MJ; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Lee H; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Yao S; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Irwin S; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Hwang S; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Belanger K; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., de Mare SW; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Surgenor R; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Yan L; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Gee P; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Morla S; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Puyang X; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Hsiao P; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Zeng H; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Zhu P; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Korpal M; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Dransfield P; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Bolduc DM; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States., Larsen NA; H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States.
Publikováno v: Biochemistry [Biochemistry] 2023 Jul 18; Vol. 62 (14), pp. 2147-2160. Date of Electronic Publication: 2023 Jul 05.
Zobrazit plný text záznamu
4
Akademický článek
Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists.
Autor: Irwin S; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Karr C; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Furman C; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Tsai J; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Gee P; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Banka D; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Wibowo AS; Shamrock Structures, LLC, Illinois, USA., Dementiev AA; Shamrock Structures, LLC, Illinois, USA., O'Shea M; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Yang J; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Lowe J; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Mitchell L; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Ruppel S; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Fekkes P; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Zhu P; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Korpal M; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA., Larsen NA; Department of Drug Discovery, H3 Biomedicine, Cambridge, Massachusetts, USA. Electronic address: nick.a.larsen@gmail.com.
Publikováno v: The Journal of biological chemistry [J Biol Chem] 2022 Nov; Vol. 298 (11), pp. 102539. Date of Electronic Publication: 2022 Sep 28.
Zobrazit plný text záznamu
5
Akademický článek
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Autor: Furman C; H3 Biomedicine Inc., Cambridge, Massachusetts., Puyang X; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhang Z; H3 Biomedicine Inc., Cambridge, Massachusetts., Wu ZJ; H3 Biomedicine Inc., Cambridge, Massachusetts., Banka D; H3 Biomedicine Inc., Cambridge, Massachusetts., Aithal KB; Aurigene Discovery Technologies Ltd, Bangalore, Karnataka, India., Albacker LA; Foundation Medicine Inc., Cambridge, Massachuetts., Hao MH; H3 Biomedicine Inc., Cambridge, Massachusetts., Irwin S; H3 Biomedicine Inc., Cambridge, Massachusetts., Kim A; H3 Biomedicine Inc., Cambridge, Massachusetts., Montesion M; Foundation Medicine Inc., Cambridge, Massachuetts., Moriarty AD; START, Preclinical Research, San Antonio, Texas., Murugesan K; Foundation Medicine Inc., Cambridge, Massachuetts., Nguyen TV; H3 Biomedicine Inc., Cambridge, Massachusetts., Rimkunas V; H3 Biomedicine Inc., Cambridge, Massachusetts., Sahmoud T; H3 Biomedicine Inc., Cambridge, Massachusetts., Wick MJ; START, Preclinical Research, San Antonio, Texas., Yao S; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhang X; H3 Biomedicine Inc., Cambridge, Massachusetts., Zeng H; H3 Biomedicine Inc., Cambridge, Massachusetts., Vaillancourt FH; H3 Biomedicine Inc., Cambridge, Massachusetts., Bolduc DM; H3 Biomedicine Inc., Cambridge, Massachusetts., Larsen N; H3 Biomedicine Inc., Cambridge, Massachusetts., Zheng GZ; H3 Biomedicine Inc., Cambridge, Massachusetts., Prajapati S; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhu P; H3 Biomedicine Inc., Cambridge, Massachusetts., Korpal M; H3 Biomedicine Inc., Cambridge, Massachusetts.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Jun 01; Vol. 21 (6), pp. 890-902.
Zobrazit plný text záznamu
6
Akademický článek
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.
Autor: Gao X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina., Wang Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Ribeiro CF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Manokaran C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Chang H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Von T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Rodrigues S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Cizmecioglu O; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Jia S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Korpal M; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Korn JM; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Wang Z; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schmit F; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Jiang L; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pagliarini R; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Yang Y; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Sethi I; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Signoretti S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Yuan GC; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Loda M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Zhao JJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Roberts TM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2022 May 04; Vol. 20 (5), pp. 673-685.
Zobrazit plný text záznamu
7
Akademický článek
The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors.
Autor: Liaghat, Mahsa1,2 (AUTHOR), Ferdousmakan, Saeid3 (AUTHOR), Mortazavi, Seyedeh Haniyeh4 (AUTHOR), Yahyazadeh, Sheida5 (AUTHOR), Irani, Asrin6 (AUTHOR), Banihashemi, Sara7 (AUTHOR), Seyedi Asl, Fatemeh Sadat8 (AUTHOR), Akbari, Abdullatif2,9 (AUTHOR), Farzam, Farnoosh10 (AUTHOR), Aziziyan, Fatemeh2,10 (AUTHOR), Bakhtiyari, Maryam2,11 (AUTHOR), Arghavani, Mohammad Javad12 (AUTHOR), Zalpoor, Hamidreza2,9 (AUTHOR) hamidreza.zlpr1998@gmail.com, Nabi-Afjadi, Mohsen10 (AUTHOR) mohsen.nabiafjadi@modares.ac.ir
Publikováno v: Cell Communication & Signaling. 12/2/2024, Vol. 22 Issue 1, p1-24. 24p.
Zobrazit plný text záznamu
8
Akademický článek
Single-Cell Analysis of Bone-Marrow-Disseminated Tumour Cells.
Autor: So, Kevin Wang Leong1 (AUTHOR) kevinswl@connect.hku.hk, Su, Zezhuo1 (AUTHOR), Cheung, Jason Pui Yin1 (AUTHOR), Choi, Siu-Wai1 (AUTHOR) htswchoi@hku.hk
Publikováno v: Diagnostics (2075-4418). Oct2024, Vol. 14 Issue 19, p2172. 22p.
Zobrazit plný text záznamu
9
Akademický článek
The Use of Patient-Derived Organoids in the Study of Molecular Metabolic Adaptation in Breast Cancer.
Autor: Glibetic, Natalija1,2,3 (AUTHOR) natalija.glibetic@chaminade.edu, Bowman, Scott1,4 (AUTHOR) scott.bowman@student.chaminade.edu, Skaggs, Tia1,5 (AUTHOR) tia.skaggs@student.chaminade.edu, Weichhaus, Michael1 (AUTHOR) michael.weichhaus@chaminade.edu
Publikováno v: International Journal of Molecular Sciences. Oct2024, Vol. 25 Issue 19, p10503. 29p.
Zobrazit plný text záznamu
10
Akademický článek
Comparative study between P- POSSUM and Apache II scores in predicting outcomes of perforation peritonitis: Prospective observational cohort study.
Autor: Yelamanchi R; Department of Surgery, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar LohiaHospital, New Delhi, 110001, India. Electronic address: raghavyelamanchi@gmail.com., Gupta N; Department of Surgery, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar LohiaHospital, New Delhi, 110001, India., Durga CK; Department of Surgery, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar LohiaHospital, New Delhi, 110001, India., Korpal M; Department of Surgery, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar LohiaHospital, New Delhi, 110001, India.
Publikováno v: International journal of surgery (London, England) [Int J Surg] 2020 Nov; Vol. 83, pp. 3-7. Date of Electronic Publication: 2020 Sep 11.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje